Pre-operative THP Achieves Pathological Complete Response in Two-Thirds of Early-Stage HER2-Positive, ER-Negative Breast Cancer Patients
In recent advancements within the realm of breast cancer therapy, the CompassHER2 pCR trial emerges as a beacon of hope ...
